Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Teva Pharmaceutical Industries Limited < Previous 1 2 3 4 5 Next > Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 28, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma December 14, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity December 06, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment November 30, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers SNY TEVA Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference November 20, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S. November 17, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program November 13, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers RPRX TEVA Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance November 08, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business November 07, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting November 02, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry November 01, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program October 25, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder October 17, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023 October 06, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment October 04, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers SNY TEVA Teva Announces Changes to Executive Management Team September 28, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference September 06, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023 September 06, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Settles Price Fixing Charges With U.S. DOJ August 21, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports Second Quarter 2023 Financial Results August 02, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development July 27, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership July 24, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023 July 05, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine June 30, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients June 15, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims June 12, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara® June 12, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers ALVO TEVA Teva Concludes Nationwide Opioids Settlement Agreement June 08, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023 June 02, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting May 20, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.